Former Dodgers closer Eric Gagne alleges widespread PED use

Former Cy Young award-winning closer Eric Gagne is pulling a Jose Canseco with his new biography.

In the French-language book, titled “Game Over: The Story of Eric Gagne,” the right-handed reliever and admitted human growth hormone user alleges that 80 percent of his Los Angeles Dodgers teammates were using performance-enhancing drugs while he was with the team, according to an ESPN.com report.

“I was intimately aware of the clubhouse in which I lived,” Gagne says in the book. “I would say that 80 percent of the Dodgers players were consuming them.”

Unlike Canseco, Gagne does not name names.

The 36-year-old French Canadian set a major league record by converting 84 consecutive saves from 2002 to 2004. He won the 2003 National League Cy Young award with the Dodgers, but injuries plagued the final four years of his career.

Gagne, who was listed in the 2006 Mitchell Report, admitted to using HGH in a 2010 interview with the Los Angeles Times while he was attempting a comeback in the Dodgers’ minor league system.

“It was sufficient to ruin my health, tarnish my reputation and throw a shadow over the extraordinary performances of my career,” Gagne says in the book.

San Francisco Giants outfielder Melky Cabrera and veteran Oakland A’s pitcher Bartolo Colon were suspended 50 games for testing positive for testosterone this season.

Follow us: @MattBrooksWP | @CindyBoren

More

Can a closer win the Cy Young?

Melky Cabrera apologizes after being suspended 50 games for PED use

Bartolo Colon suspended 50 games after testing positive for testosterone

Matt Brooks is the high school sports editor for The Washington Post. He's an Arlington native and longtime District resident and was previously a high school sports reporter, editor for several blogs and Early Lead contributor with The Post.

sports

Success! Check your inbox for details. You might also like:

Please enter a valid email address

See all newsletters

Comments
Show Comments
Most Read

sports

Success! Check your inbox for details.

See all newsletters